edoc

High-dose daunorubicin in older patients with acute myeloid leukemia

Löwenberg, and Bob, and Ossenkoppele, and Gert, J. and van Putten, and Wim, and Schouten, and Harry, C. and Graux, and Carlos, and Ferrant, and Augustin, and Sonneveld, and Pieter, and Maertens, and Johan, and Jongen-Lavrencic, and Mojca, and von Lilienfeld, Toal and Marie, and Biemond, and Bart, J. and Vellenga, and Edo, and van Marwijk, Kooy and Marinus, and Verdonck, and Leo, F. and Beck, and Joachim, and Döhner, and Hartmut, and Gratwohl, and Alois, and Pabst, and Thomas, and Verhoef, and Gregor, and Dutch-Belgian, Cooperative Trial Group for Hemato-Oncology and German, AML Study Group. (2009) High-dose daunorubicin in older patients with acute myeloid leukemia. The New England journal of medicine, Vol. 361. pp. 1235-1248.

Full text not available from this repository.

Official URL: http://edoc.unibas.ch/dok/A6006284

Downloads: Statistics Overview

Abstract

A complete remission is essential for prolonging survival in patients with acute myeloid leukemia (AML). Daunorubicin is a cornerstone of the induction regimen, but the optimal dose is unknown. In older patients, it is usual to give daunorubicin at a dose of 45 to 50 mg per square meter of body-surface area.
Faculties and Departments:03 Faculty of Medicine > Bereich Medizinische Fächer (Klinik) > Ehemalige Einheiten Medizinische Fächer (Klinik) > Hämatologie (Gratwohl)
03 Faculty of Medicine > Departement Klinische Forschung > Bereich Medizinische Fächer (Klinik) > Ehemalige Einheiten Medizinische Fächer (Klinik) > Hämatologie (Gratwohl)
UniBasel Contributors:Gratwohl, Alois A.
Item Type:Article, refereed
Article Subtype:Research Article
Bibsysno:Link to catalogue
Publisher:Massachusetts Medical Society
ISSN:1533-4406
Note:Publication type according to Uni Basel Research Database: Journal article
Related URLs:
Identification Number:
Last Modified:01 Feb 2013 08:46
Deposited On:01 Feb 2013 08:45

Repository Staff Only: item control page